CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Significant Growth in Short Interest

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, an increase of 26.2% from the November 30th total of 4,390,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 4.8 days.

CytomX Therapeutics Trading Down 4.7 %

Shares of NASDAQ CTMX opened at $1.02 on Tuesday. The stock has a 50-day moving average price of $1.05 and a two-hundred day moving average price of $1.18. CytomX Therapeutics has a 12 month low of $0.83 and a 12 month high of $5.85. The company has a market cap of $79.82 million, a price-to-earnings ratio of 6.00 and a beta of 1.07.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same quarter last year, the business posted $0.04 earnings per share. On average, sell-side analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.77.

Hedge Funds Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics during the third quarter worth about $104,000. Geode Capital Management LLC grew its holdings in CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 34,032 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 16,359 shares during the period. FMR LLC raised its stake in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after acquiring an additional 41,949 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of CytomX Therapeutics by 10.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 26,373 shares during the period. Institutional investors and hedge funds own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.